Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by toinv261on Jan 22, 2016 10:56am
193 Views
Post# 24483941

Hepalink Effect

Hepalink EffectHi folks.

We all know that many very positive things can happen between now and the BETonMACE trial results in 2018 and many lists have been posted. (epigenetic momentum, regional deals, orphan trials, further understanding of the MOA of rvx-208, success of the 3 month ZEN 3694 prostate cancer trial with results this summer (lends credibility to BET inhibition and hence rvx-208),etc).

One thing that just occurred to me is the potential Hepalink effect. Hepalink is an insider and they will be doing the China, Taiwan, Macau trials. They will probably also be doing their own scientific research on the MOA of rvx-208. They have access to armies of top rate scientists to check out this molecule. Hepalink is a downstream pharma company and the sooner they get rvx-208 to market the sooner their balance sheet improves. Hepalink has a presence in the USA via a takeover in the past few years. Obviously Hepalink already has a strong belief in rvx-208 regarding MACE reduction because they are funding the full BETonMACE trial. Therefore if they begin to sniff a very high probability of BETonMACE success as they move through the trial OR if they begin to understand the applications of rvx-208(or other RVX compounds) for other indications they may move fairly quickly toward a buyout of Resverlogix and perhaps ZEL before other pharma can make the move.I

Don mentioned a possible large deal regarding ZEL or parts thereof in China.

There is a lot going on at both ZCC and RVX in terms of science and deals so perhaps we'll see action of the investment side sooner than later. The momentum is building. This could be the deal that launches Hepalink well above it's current limited portfolio and makes them a significant global player.

Hepalink could be the ace. They have the knowledge and $$$$ to by RVX and if things heat up they may move fast.

The failures by major pharmas using the benzodiazepine scaffold could turn some investors away from epigenetics OR focus them on the ASSURE and SUSTAIN successes with rvx-208.

We'll see but it may not take the full trial before this stock blows through the roof as I had been thinking previously.
GLTA
Toinv
I having problems with SH.
Bullboard Posts